TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.

R J Kelly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.